Hypofractionated radiotherapy for breast cancer patients with prosthetic reconstruction

Randomized Phase III Clinical Trial of Hypofractionated Radiotherapy in Breast Cancer Patients With Immediate Prosthetic Reconstruction: PROMART Trial

NA · Barretos Cancer Hospital · NCT05491395

This study is testing a shorter course of radiation therapy for women with breast cancer who have had breast implants to see if it causes fewer complications and helps them feel better compared to standard radiation.

Quick facts

PhaseNA
Study typeInterventional
Enrollment120 (estimated)
Ages18 Years and up
SexFemale
SponsorBarretos Cancer Hospital (other)
Drugs / interventionschemotherapy
Locations1 site (Barretos, São Paulo)
Trial IDNCT05491395 on ClinicalTrials.gov

What this trial studies

This study evaluates the safety and effectiveness of hypofractionated radiotherapy in women with breast cancer who have undergone immediate prosthetic reconstruction. It aims to determine the rate of severe complications, such as capsular contracture and prosthesis loss, and compares these outcomes to those of patients receiving conventional radiotherapy. Additionally, the study will assess local recurrence rates, quality of life, and molecular markers related to inflammation and fibrosis. The research will involve analyzing patient-derived blood samples to understand the biological factors contributing to complications.

Who should consider this trial

Good fit: Ideal candidates are women over 18 with invasive ductal or lobular breast carcinoma who have undergone radical mastectomy with immediate prosthetic reconstruction and are indicated for adjuvant radiotherapy.

Not a fit: Patients with other types of breast cancer histology, previous cancer treatments, or distant metastatic disease may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could provide a safer radiotherapy option that minimizes complications for breast cancer patients with prosthetic reconstruction.

How similar studies have performed: While there is limited consensus on hypofractionated radiotherapy for this specific patient population, similar studies have shown promising results in other contexts, suggesting potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Women with confirmed histological diagnosis of invasive ductal carcinoma and lobular breast carcinoma;
* Radical mastectomy with immediate reconstruction with a prosthesis;
* Patients indicated for adjuvant RT;
* Any lymph node status;
* With or without adjuvant chemotherapy;
* ECOG performance status from 0-2;
* \> 18 years old;
* Informed Consent Form applied before any study-specific procedure.

Exclusion Criteria:

* Another histological diagnosis than invasive ductal carcinoma or lobular carcinoma;
* Previous history of neoplasm and/or radiotherapy and/ or quimiotherapy before this study;
* Distant metastatic disease;
* Palliative treatment;
* Patients with scleroderma / systemic lupus erythematosus.

Where this trial is running

Barretos, São Paulo

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Breast Cancer, breast cancer, radiation therapy, hypofractionated, biomarkers

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.